secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2023-09-19T23:59:59+00:00
Accession:  0001104659-23-101780
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia sells Orthobiologics unit to Berkeley Biologics for up to $35M
---------------------------------------------------------------------

- Upfront cash $15M at close; earn-out payments up to $20M over 5 years (10% of annual revenue from Earn-Out Products, capped at $20M).
- Transaction expected to close in Q4 2023; subject to customary conditions including regulatory approvals and material consents.
- Elutia to focus on drug-eluting biomatrix platform; lead product CanGaroo RM targets FDA clearance and launch in H1 2024.
- Berkeley Biologics is a wholly-owned subsidiary of GNI Group Ltd. (Tokyo: 2160.T).
- Elutia will enter a Manufacturing Agreement for SimpliDerm product for two years following closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465923101780/0001104659-23-101780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465923101780/tm2326344d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-101780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer